Introduction to Insulatard NPH Human
Insulatard NPH Human is a suspension for injection containing human insulin, used to treat both type 1 and type 2 diabetes. It is available in various forms, including vials, cartridges (Penfill), and pre-filled pens (InnoLet or FlexPen)[1].
Clinical Trials and Efficacy
Insulatard has been extensively studied in several clinical trials to assess its efficacy and safety. Here are the key findings:
- Patient Population: The clinical trials involved a total of 557 patients, with 81 patients having type 1 diabetes and 476 patients having type 2 diabetes[1].
- Comparison with Other Insulins: Insulatard was compared with other types of human insulin and insulin analogues. The studies measured fasting blood glucose levels and glycosylated hemoglobin (HbA1c) to assess blood glucose control[1].
- Results: The trials showed that Insulatard led to a decrease in HbA1c levels, indicating effective blood sugar control similar to other human insulins. It was effective for both type 1 and type 2 diabetes, whether administered via standard injection or pre-filled pens[1].
- Administration Methods: Additional studies compared the use of Insulatard via syringes and pre-filled pens (InnoLet or FlexPen) in 225 patients, confirming its efficacy across different delivery methods[1].
Common Side Effects
The most common side effect associated with Insulatard is hypoglycemia (low blood glucose levels), which occurs in more than 1 in 10 patients[1].
Market Analysis
Global Human Insulin Market Overview
The global human insulin market is experiencing significant growth driven by several factors:
- Increasing Diabetes Prevalence: The rising number of diabetic patients worldwide is a major driver. By 2030, the global human insulin market is expected to grow from USD 45 billion in 2022 to USD 83.29 billion, at a CAGR of 8%[2].
- Distribution Channels: Retail pharmacies dominate the market, holding around 48.8% of the market share in 2022. This segment is expanding due to growing disease burden, home care viability, and discounts offered by retail pharmacies[2].
- Regional Analysis: North America leads the market with a 39.1% share in 2022, while the Asia-Pacific region is expected to grow the fastest due to increasing diabetes prevalence and strengthening distribution networks[2][3].
Market Segmentation
- By Type: The market is segmented into classic and modern human insulin. Modern human insulin, including analogues, led the market with a 62.3% share in 2022[2].
- By Distribution Channel: Retail pharmacies, hospitals, and online pharmacies are key distribution channels. Retail pharmacies are expected to continue their dominance due to technological advancements in insulin delivery systems[5].
- By Application: The market is primarily driven by the treatment of type 1 and type 2 diabetes. The senior population, projected to quadruple by 2050, is another significant factor influencing market growth[2].
Technological Advancements
The market is also driven by innovations in insulin delivery systems:
- Inhaled Insulin: Products like Afrezza (Mannkind) offer alternatives to traditional injections[2].
- Oral Insulin: Oramed Pharmaceuticals is conducting phase 3 clinical studies for an oral insulin capsule, which could provide another treatment option by Q4 2023[2].
Market Projections
Growth Rate and Market Size
The global human insulin market is projected to grow at a CAGR of 8.1% from 2023 to 2030. This growth is attributed to the increasing diabetes patient population, technological advancements in delivery devices, and favorable medical reimbursements[3].
Regional Growth
- North America: This region dominates the market and is expected to continue its leadership due to technological developments in insulin delivery products[5].
- Asia-Pacific: This region is poised to grow the fastest due to the large diabetic and pre-diabetic population, strengthening distribution networks, and evolving regulatory frameworks[3].
Challenges and Opportunities
Despite the growth, the market faces challenges such as stringent regulatory requirements for product approval and high manufacturing costs. However, strategies like geography expansion, product development, partnerships, and awareness campaigns are being adopted by major players to strengthen their market positions[3].
Key Takeaways
- Efficacy and Safety: Insulatard has been proven effective in controlling blood sugar levels in both type 1 and type 2 diabetes patients.
- Market Growth: The global human insulin market is expected to grow significantly, driven by increasing diabetes prevalence and technological advancements.
- Distribution and Innovation: Retail pharmacies are dominant, and innovations in delivery systems are expanding treatment options.
- Regional Dynamics: North America leads the market, while the Asia-Pacific region is expected to grow the fastest.
FAQs
What is Insulatard NPH Human used for?
Insulatard NPH Human is used to treat both type 1 and type 2 diabetes by controlling blood sugar levels.
What are the common side effects of Insulatard?
The most common side effect is hypoglycemia (low blood glucose levels), occurring in more than 1 in 10 patients.
How is Insulatard administered?
Insulatard can be administered via standard injection using a syringe or through pre-filled pens (InnoLet or FlexPen).
What is the projected growth rate of the global human insulin market?
The global human insulin market is projected to grow at a CAGR of 8.1% from 2023 to 2030.
Which region dominates the global human insulin market?
North America currently dominates the market, but the Asia-Pacific region is expected to grow the fastest.
Sources
- European Medicines Agency (EMA). Insulatard | European Medicines Agency (EMA).
- GreyViews. Human Insulin Market- Size| Growth| Market Analysis Till 2030.
- MarketsandMarkets. Human Insulin Market Revenue Forecast | Latest Industry Updates.
- PubMed. Different absorption of isophane (NPH) insulin from subcutaneous ...
- Verified Market Research. Human Recombinant Insulin Market Size & Forecast.
